Home › Colorectal Cancer › Pennsylvania
Colorectal Cancer clinical trials in Pennsylvania
69 studies for Colorectal Cancer are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
- Philadelphia44 studies
- Pittsburgh32 studies
- Harrisburg7 studies
- Allentown7 studies
- Scranton5 studies
- Hazleton5 studies
- York4 studies
- Reading3 studies
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Penn State Milton S. Hershey Medical Center, Hershey
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06324357A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05877599Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05803382Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- University of Pittsburgh Medical Center (UPMC), Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05482893A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Thomas Jefferson University, Philadelphia
- Fox Chase Cancer Center, Philadelphia
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06662786Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Philadelphia
- Research Site, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06218914A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- Alliance Cancer Specialists at Main Line, Penn Wynne
- Thomas Jefferson University, Philadelphia
- Fox Chase Cancer Center, Philadelphia
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06750094A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
- GSK Investigational Site, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07277270Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Saint Vincent Hospital, Erie
- Jefferson Hospital, Jefferson Hills
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT05863195A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Lehigh Valley Health Network, Allentown
- Local Institution - 0604, Pittsburgh
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07221357Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Allegheny Health Network, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Hospital of the University of Pennsylvania, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06445062A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- University of Pennsylvania, Philadelphia
- Fox Chase Cancer Center, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213791A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07114601The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
- WellSpan York Cancer Center, York
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT04585750A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Alliance Cancer Specialists, Doylestown
- Penn State Milton S. Hershey Medical Center, Hershey
- University of Pennsylvania, Philadelphia
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07284849SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT07812805Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- Clinical Study Site, Lebanon
- Clinical Study Site, Philadelphia
- Clinical Study Site, Philadelphia
- and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT07228832Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
- Christiana Care Health System-Concord Health Center, Chadds Ford
- Geisinger Medical Center, Danville
- Penn State Milton S Hershey Medical Center, Hershey
- and 4 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT05673148FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07216105Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Geisinger Medical Center, Danville
- and 7 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069Family Communications After Genetic Testing
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Pocono Medical Center, East Stroudsburg
- and 2 more
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07143487A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
- UPenn Lancaster-Ann B. Barshinger Cancer Institute, Lancaster
- Thomas Jefferson University - Sidney Kimmel Comprehensive Cancer Center, Philadelphia
- UPMC / University of Pittsburgh Medical Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT06992258Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT06586515A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07235293Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients
- University of Pennsylvania, Philadelphia
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT05410977FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264TCR1188-ABC Cells in KRAS-mutated Cancers
- University of Pennsylvania, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07594067Safety and Effectiveness Evaluation of the COLO-BT as an Alternative Treatment to the Ileostomy
- PennState Health - Milton S. Hershey Medical Center, Hershey
RecruitingHealthy volunteers welcome
Ages 19 to 80 · All sexes · Updated Aug 5, 2026 · NCT05826743Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #104, Hershey
- Exelixis Clinical Site #98, Philadelphia
- Exelixis Clinical Site #32, Pittsburgh
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT05176483Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT05691491Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT06654037A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- University of Pennsylvania / Abramson Cancer Center, Philadelphia
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT04657068AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- Thomas Jefferson University, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT07094113A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- University of Pennsylvania, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 29, 2026 · NCT03526835A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Jefferson University Hospitals, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT06179160A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
- UPMC Hillman Cancer Center - Beaver, Beaver
- UPMC Hillman Cancer Center at Butler Health System, Butler
- UPMC Hillman Cancer Center Erie, Erie
- and 10 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT05253651A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT06948448A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT06657144From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.